Method for producing triazolopyrimidinone derivatives
A streamlined synthetic route for triazolopyrimidinone derivatives addresses the inefficiencies of existing methods by reducing steps and eliminating microwave and column purification, enabling high-purity, high-yield, and cost-effective mass production.
Patent Information
- Application Number
- JP2024531076
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-12-01
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2041-12-01
AI Technical Summary
The existing method for producing triazolopyrimidinone derivatives, as described in International Publication No. WO2016/006974, is not suitable for mass production due to the use of microwaves and column purification, leading to inefficiencies and high production costs.
A novel synthetic route involving fewer steps and eliminating microwave reactions, allowing for high-purity and high-yield production of triazolopyrimidinone derivatives through crystallization without purification, reducing unit production costs.
The new method enables efficient mass production of triazolopyrimidinone derivatives with high purity and yield, making it economically viable by minimizing the number of steps and eliminating the need for costly purification processes.
Smart Images

Figure 2024541104000001 
Figure 2024541104000002 
Figure 2024541104000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing triazolopyrimidinone derivatives exhibiting tankyrase inhibitory activity. [Background technology]
[0002] Tankyrase belongs to the protein family of poly(ADP-ribose)polymerase (PARP), which consists of 17 members that share the catalytic PARP domain. Recently, it has been reported that the levels of intracellular axin are influenced by the PARP enzyme family members tankyrase-1 and tankyrase-2 (also known as PARP5a and PARP5b, respectively) (Huang et al., 2009, Nature, 461(7264):614-620).
[0003] Inhibitors of tankyrase-1 and tankyrase-2 are known to have therapeutic potential for a variety of cancer diseases, including solid cancers such as colorectal carcinoma, colon cancer, gastric cancer, hepatocellular carcinoma, breast cancer, medulloblastoma, melanoma, non-small cell lung cancer, pancreas adenocarcinoma, and prostate cancer. In addition to the above cancer diseases, inhibitors of tankyrase-1 and tankyrase-2 also have therapeutic potential for other diseases, including osteoporosis, osteoarthritis, polycystic kidney disease, pulmonary fibrosis, diabetes, schizophrenia, vascular disease, cardiac disease, non-oncogenic proliferative diseases, and neurodegenerative diseases such as Alzheimer's disease.
[0004] As described above, there is a continuing need for new therapeutic agents that can be used for cancer and hyperproliferative conditions, and attempts are being made to develop new pharmaceutical compounds that can selectively inhibit the Tankyrase enzyme. In particular, triazolopyrimidinone derivatives of the following formula I are known as selective Tankyrase inhibitors, and are being developed as therapeutic agents for colon cancer in patients with a colon cancer-inducing gene (KRAS) mutation genotype or in patients who do not respond to Erbitux. [ka]
[0005] International Publication WO2016 / 006974 discloses a method for producing triazolopyrimidinone derivatives including the compound of formula I. However, the method requires a microwave reaction step and column purification, making it unsuitable for mass production, and therefore the process needs to be improved.
[0006] Therefore, it is necessary to develop a new method for producing the triazolopyrimidinone derivative compound of Formula I with high purity by improving the above-mentioned inefficient production method. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] International Publication No. 2016 / 006974 [Non-patent literature]
[0008] [Non-Patent Document 1] Huang et al., 2009, Nature, 461(7264):614-620 Summary of the Invention [Problem to be solved by the invention]
[0009] The object of the present invention is to provide a method for producing triazolopyrimidinone derivatives with high purity and high yield, thereby reducing the production cost and making it suitable for mass production through efficient process steps.
[0010] Another object of the present invention is to provide a novel intermediate for use in the above-mentioned production method. [Means for solving the problem]
[0011] The present invention provides a method for preparing a triazolopyrimidinone derivative represented by the following formula I: [ka]
[0012] According to an embodiment of the present invention, the triazolopyrimidinone derivative represented by Formula I can be prepared via the following synthetic route A or B.
[0013] <Synthetic Route A> Among the production methods of the present invention, synthetic route A includes the following steps (A-1) to (A-8). (A-1) a first step of preparing a compound represented by the following chemical formula 2 by a protection reaction from a compound represented by the following chemical formula 1 or a salt thereof; (A-2) a second step of preparing a compound represented by the following chemical formula 3 from the compound represented by the chemical formula 2 by oxidation reaction; (A-3) a third step of preparing a compound represented by the following chemical formula 5 from a compound represented by the following chemical formula 4 by an amination reaction; (A-4) a fourth step of preparing a compound represented by the following formula 6 from the compound represented by the formula 5 by Dakin reaction; (A-5) a fifth step of preparing a compound represented by the following formula 7 from the compound represented by the formula 6 by alkylation reaction; (A-6) a sixth step of preparing a compound represented by the following chemical formula 8 or a salt thereof from the compound represented by the chemical formula 7 by a deprotection reaction; (A-7) a seventh step of preparing a compound represented by the following formula Ia by an amination reaction of the compound represented by the formula 3 and the compound represented by the formula 8 or a salt thereof; and (A-8) The compound represented by the above chemical formula Ia is subjected to a deprotection reaction to obtain the following chemical formula: Step 8: preparing a compound represented by I; [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] In the above chemical formula, R is an O-protecting group; A is an N-protecting group.
[0014] Hereinafter, the steps (A-1) to (A-8) will be described separately.
[0015] <(A-1) Stage> In the present invention, the step (A-1) is a step of preparing a compound represented by Chemical Formula 2 by a protection reaction using a triazolopyrimidinone derivative compound represented by Chemical Formula 1 or a salt thereof as a starting material (Reaction Scheme 1). [ka] In the above formula, R is an O-protecting group.
[0016] According to an embodiment of the present invention, the reaction is to protect a triazolopyrimidinone derivative. For example, R may be C1-C6 alkyl, acetyl, benzoyl, benzyl, p-methoxybenzyl, MOM (methoxymethyl acetal), THP (tetrahydropyran) or silyl ether. According to an embodiment of the present invention, the reaction is to react a compound of Chemical Formula 1 with an alkyl halide to prepare a compound of Chemical Formula 2. For example, R may be isopropyl, and the reaction may be carried out by an alkylation reaction with 2-iodopropane, but is not limited thereto.
[0017] In the reaction, a base that is usually used in a protection reaction can be used. For example, the base can be sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, cesium carbonate or cesium fluoride. Specifically, cesium fluoride (CsF) can be used, but is not limited thereto.
[0018] In the reaction, an organic solvent that is usually used in a protection reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, or a mixture thereof. Specifically, dimethylformamide can be used, but is not limited thereto.
[0019] The reaction may be carried out at a temperature of 30 to 110° C., more specifically, at a temperature of 60 to 90° C., but is not limited thereto. After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the reaction product was stirred in isopropanol, an organic solvent, to obtain a high-purity product.
[0020] <(A-2) Stage> In the present invention, the step (A-2) is a step of preparing a compound represented by Chemical Formula 3 by oxidation reaction using a triazolopyrimidine derivative compound represented by Chemical Formula 2 as a starting material (Reaction Scheme 2). [ka] In the above chemical formula, R is as defined above.
[0021] According to an embodiment of the present invention, the reaction can be carried out by an oxidation reaction in which the compound represented by Formula 2 is reacted with an oxidizing agent.
[0022] In the reaction, an oxidizing agent that is generally used in an oxidation reaction can be used. For example, the oxidizing agent can be hydrogen peroxide, benzoyl peroxide, metachloroperbenzoic acid, or oxone. Specifically, oxone can be used, but is not limited thereto.
[0023] In the reaction, an organic solvent that is usually used in an oxidation reaction can be used. For example, the solvent can be tetrahydrofuran, 1,4-dioxane, acetone, methanol, ethanol, isopropanol, water, or a mixture thereof. Specifically, a mixture of tetrahydrofuran and methanol can be used, but is not limited thereto.
[0024] The reaction may be carried out at a temperature of 0 to 70° C., more specifically, at a temperature of 30 to 50° C., but is not limited thereto.
[0025] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the reaction product was stirred in isopropanol, an organic solvent, to obtain a high-purity product.
[0026] <(A-3) Stage> In the present invention, the step (A-3) is a step of preparing a compound represented by Chemical Formula 5 by an amination reaction using a trifluorobenzaldehyde derivative compound represented by Chemical Formula 4 as a starting material (Reaction Scheme 3). [ka] In the above formula, A is an N-protecting group.
[0027] According to an embodiment of the present invention, the reaction can be carried out by using a trifluorobenzaldehyde derivative and a protected piperazine derivative. For example, A can be -Boc, -Cbz, -Fmoc, -benzyl, p-methoxybenzyl, trityl or DMT (dimethoxytrityl). According to an embodiment of the present invention, the reaction can be carried out by an amination reaction in which 3,4,5-trifluorobenzaldehyde is reacted with N-Boc-piperazine, but is not limited thereto.
[0028] In the reaction, a base that is generally used in an amination reaction can be used. For example, the base can be lithium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, or cesium carbonate. Specifically, lithium carbonate can be used, but is not limited thereto.
[0029] In the reaction, an organic solvent that is usually used in an amination reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, or a mixture thereof. Specifically, dimethylsulfoxide can be used, but is not limited thereto.
[0030] The reaction may be carried out at a temperature of 80 to 150° C., more specifically, at a temperature of 110 to 130° C., but is not limited thereto.
[0031] After the reaction, one or more steps of separating or purifying the product may be further carried out, but is not limited thereto.
[0032] <(A-4) Stage> In the present invention, the step (A-4) is a step of preparing a compound represented by Chemical Formula 6 by Dakin reaction using a phenylpiperazine derivative compound represented by Chemical Formula 5 as a starting material (Reaction Scheme 4). [ka] In the above formula, A is as defined above.
[0033] According to an embodiment of the present invention, the reaction can be carried out by adding an oxidizing agent to the compound represented by formula 5.
[0034] The Dakin reaction can be carried out using a commonly used oxidizing agent. For example, hydrogen peroxide, ammonium persulfate, metachloroperbenzoic acid (mCPBA), or a mixture thereof can be used. Specifically, metachloroperbenzoic acid can be used, but is not limited thereto.
[0035] After the reaction, when hydrolysis is performed on the resulting intermediate (phenyl formate), a base that is usually used can be used. For example, the base can be lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, or calcium carbonate. Specifically, sodium hydroxide can be used, but is not limited thereto.
[0036] A commonly used solvent can be used in the reaction. For example, the solvent can be dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, acetone, methanol, ethanol, isopropanol, water, or a mixture thereof. Specifically, dichloromethane can be used, but is not limited thereto.
[0037] The reaction may be carried out at a temperature of -20 to 30°C, more specifically, at a temperature of -15 to 15°C, but is not limited thereto.
[0038] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. For example, in an embodiment of the present invention, the reaction product was stirred in isopropanol, an organic solvent, to obtain a high-purity product.
[0039] <(A-5) Stage> In the present invention, the step (A-5) is a step of preparing a compound represented by Chemical Formula 7 by alkylation reaction using a phenylpiperazine derivative compound represented by Chemical Formula 6 as a starting material (Reaction Scheme 5). [ka] In the above formula, A is as defined above.
[0040] According to an embodiment of the present invention, the reaction can be carried out by an alkylation reaction of the compound of formula 6 with 1-halo-2-methoxyethane (eg, 1-bromo-2-methoxyethane).
[0041] In the reaction, an organic solvent that is usually used in an alkylation reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, or a mixture thereof. Specifically, acetonitrile can be used, but is not limited thereto.
[0042] The reaction may be carried out at a temperature of 50 to 100° C., more specifically, 75 to 85° C., but is not limited thereto.
[0043] <(A-6) Stage> In the present invention, the step (A-6) is a step of preparing a compound represented by Chemical Formula 8 or a salt thereof by deprotection reaction using a phenylpiperazine derivative compound represented by Chemical Formula 7 as a starting material (Reaction Scheme 6). [ka] In the above formula, A is as defined above.
[0044] According to an embodiment of the present invention, the reaction can be carried out by deprotecting the compound of Formula 7 under acidic conditions.
[0045] In the reaction, a solvent that is usually used in a deprotection reaction can be used. For example, the solvent can be methanol, ethanol, isopropanol, tetrahydrofuran, acetonitrile, water, or a mixture thereof. Specifically, methanol can be used, but is not limited thereto.
[0046] The reaction can be carried out at a temperature of 0 to 60° C., more specifically, at a temperature of 30 to 50° C., but is not limited thereto.
[0047] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the product of the reaction was stirred in an organic solvent, such as dichloromethane, tert-butyl methyl ether, or a mixture thereof, to obtain a high-purity product.
[0048] <(A-7) Stage> In the present invention, the step (A-7) is a step of preparing a compound represented by the following Chemical Formula 9 by an amination reaction between a compound represented by Chemical Formula 3 and a compound represented by Chemical Formula 8 or a salt thereof (Reaction Scheme 7). [ka] In the above formula, R is as defined above.
[0049] According to an embodiment of the present invention, the reaction can be carried out by an amination reaction using, for example, 7-isopropoxy-3-methyl-5-(methylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine and 1-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazine hydrochloride.
[0050] In the reaction, a base that is generally used in an amination reaction can be used. For example, the base can be lithium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, cesium carbonate, triethylamine, diisopropylethylamine or 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU). Specifically, diisopropylethylamine can be used, but is not limited thereto.
[0051] In the reaction, an organic solvent that is usually used in an amination reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, methanol, ethanol, isopropanol, or a mixture thereof. Specifically, ethanol can be used, but is not limited thereto.
[0052] The reaction can be carried out at a temperature of 50 to 100° C., more specifically, at a temperature of 60 to 80° C., but is not limited thereto.
[0053] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the reaction product was stirred in an organic solvent such as dichloromethane, diisopropyl ether or a mixture thereof to obtain a high purity product.
[0054] <(A-8) Stage> In the present invention, the step (A-8) is a step of preparing a compound represented by Chemical Formula I from a compound represented by Chemical Formula 9 by a deprotection reaction (Reaction Scheme 8). [ka] In the above formula, R is as defined above.
[0055] According to a specific embodiment of the present invention, the reaction can be carried out, for example, by deprotection reaction of 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine.
[0056] In the reaction, an acid that is usually used in a deprotection reaction can be used as a solvent. In this case, the acid can be acetic acid, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, or a mixture thereof. Specifically, acetic acid, sulfuric acid, or a mixture thereof can be used, but is not limited thereto.
[0057] The reaction can be carried out at a temperature of 30 to 80° C., more specifically, at a temperature of 40 to 60° C., but is not limited thereto.
[0058] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the product of the reaction was stirred in acetone, water or a mixture thereof to obtain a high purity product.
[0059] <Synthetic Route B> Among the production methods of the present invention, synthetic route B includes the following steps (B-1) to (B-7). (B-1) a first step of preparing a compound represented by the following chemical formula 2 by a protection reaction from a compound represented by the following chemical formula 1 or a salt thereof; (B-2) a second step of preparing a compound represented by the following chemical formula 3 from the compound represented by the chemical formula 2 by oxidation reaction; (B-3) a third step of preparing a compound represented by the following chemical formula 9 from a compound represented by the following chemical formula 4 by an amination reaction; (B-4) a fourth step of preparing a compound represented by the following formula 10 by an amination reaction of the compound represented by the formula 3 and the compound represented by the formula 9 or a salt thereof; (B-5) a fifth step of preparing a compound represented by the following chemical formula 11 from a compound represented by the following chemical formula 10 by Dakin reaction; (B-6) a sixth step of preparing a compound represented by the following formula Ia by alkylation reaction from a compound represented by the following formula 11; and (B-7) a seventh step of preparing a compound represented by the following chemical formula I by a deprotection reaction from the compound represented by the chemical formula Ia: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] In the above chemical formula, R is an O-protecting group.
[0060] Hereinafter, the steps (B-1) to (B-7) will be described separately. Among them, the steps (B-1), (B-2) and (B-7) are the same as the steps (A-1), (A-2) and (A-8), respectively, and only the steps (B-3) to (B-6) will be specifically described.
[0061] <(B-3) Stage> In the present invention, the step (B-3) is a step of preparing a compound represented by Chemical Formula 8 or a salt thereof by an amination reaction using a trifluorobenzaldehyde derivative compound represented by Chemical Formula 4 as a starting material (Reaction Scheme 9). [ka]
[0062] According to an embodiment of the present invention, the reaction may involve a trifluorobenzaldehyde derivative and piperazine.
[0063] In the reaction, a base that is generally used in an amination reaction can be used. For example, the base can be lithium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, or cesium carbonate. Specifically, potassium carbonate can be used, but is not limited thereto.
[0064] In the reaction, an organic solvent that is generally used in an amination reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, isopropyl alcohol, dimethylsulfoxide, dimethylacetamide, dimethylformamide, ethylene glycol, diethylene glycol, dimethyl ether, dimethoxyethane, or a mixture thereof. Specifically, dimethoxyethane can be used, but is not limited thereto.
[0065] The reaction may be carried out at 60 to 150° C., more specifically, at 70 to 90° C., but is not limited thereto.
[0066] After the reaction, one or more steps of separating or purifying the product may be further carried out, but is not limited thereto.
[0067] <(B-4) Stage> In the present invention, the step (B-3) is a step of preparing a compound represented by the following Chemical Formula 10 by an amination reaction between a compound represented by Chemical Formula 3 and a compound represented by Chemical Formula 9 or a salt thereof (Reaction Scheme 10). [ka] In the above formula, R is as defined above.
[0068] According to an embodiment of the present invention, the reaction can be carried out, for example, by an amination reaction using 7-isopropoxy-3-methyl-5-(methylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine and 3,5-difluoro-4-(piperazin-1-yl)benzaldehyde.
[0069] In the reaction, a base that is generally used in an amination reaction can be used, for example, lithium carbonate, sodium carbonate, potassium carbonate, sodium bicarbonate, cesium carbonate, triethylamine, diisopropylethylamine, or 1,8-diazabicyclo[5,4,0]undec-7-ene (DBU), but is not limited thereto.
[0070] In the reaction, an organic solvent that is usually used in an amination reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, methanol, ethanol, isopropanol, or a mixture thereof. Specifically, dimethylacetamide can be used, but is not limited thereto.
[0071] The reaction can be carried out at a temperature of 50 to 150° C., more specifically, at a temperature of 80 to 120° C., but is not limited thereto.
[0072] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. In an embodiment of the present invention, the reaction product was stirred in an organic solvent, such as diethyl ether, isopropanol, or a mixture thereof, to obtain a high-purity product.
[0073] <(B-5) Stage> In the present invention, the step (B-5) is a step of preparing a compound represented by Chemical Formula 11 by Dakin reaction using a compound represented by Chemical Formula 10 as a starting material (Reaction Scheme 11). [ka] In the above formula, R is as defined above.
[0074] According to an embodiment of the present invention, the reaction can be carried out by adding an oxidizing agent to the compound of formula (10).
[0075] The Dakin reaction can be carried out using a commonly used oxidizing agent. For example, hydrogen peroxide, ammonium persulfate, metachloroperbenzoic acid (mCPBA), or a mixture thereof can be used. Specifically, metachloroperbenzoic acid can be used, but is not limited thereto.
[0076] After the reaction, when hydrolysis is performed on the resulting intermediate (phenyl formate), a base that is usually used can be used. For example, the base can be lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium carbonate, or calcium carbonate. Specifically, sodium hydroxide can be used, but is not limited thereto.
[0077] A commonly used solvent can be used in the reaction. For example, the solvent can be dichloromethane, chloroform, tetrahydrofuran, 1,4-dioxane, acetone, methanol, ethanol, isopropanol, water, or a mixture thereof. Specifically, dichloromethane can be used, but is not limited thereto.
[0078] The reaction may be carried out at -20 to 30°C, more specifically, at -15 to 15°C, but is not limited thereto.
[0079] After the reaction, one or more steps of separating or purifying the product may be further performed, but is not limited thereto. For example, in an embodiment of the present invention, the reaction product was stirred in an organic solvent, isopropanol and tert-butyl methyl ether, or a mixture thereof, to obtain a high-purity product.
[0080] <(B-6) Stage> In the present invention, the step (B-6) is a step of preparing a compound represented by formula Ia by alkylation reaction using a compound represented by formula 11 as a starting material (reaction formula 12). [ka]
[0081] According to an embodiment of the present invention, the reaction can be carried out by an alkylation reaction of the compound of formula 11 with 1-halo-2-methoxyethane (eg, 1-bromo-2-methoxyethane).
[0082] In the reaction, an organic solvent that is usually used in an alkylation reaction can be used. For example, the solvent can be acetonitrile, tetrahydrofuran, 1,4-dioxane, acetone, dimethylsulfoxide, dimethylacetamide, dimethylformamide, or a mixture thereof. Specifically, dimethylformamide can be used, but is not limited thereto.
[0083] The reaction may be carried out at a temperature of 50 to 100° C., more specifically, at 60 to 80° C., but is not limited thereto.
[0084] According to the manufacturing method disclosed in International Publication WO2016 / 006974, the compound represented by the chemical formula I is manufactured through 11 steps. In addition, the method is not suitable for mass production because it uses microwaves and requires several column purification steps. However, according to the manufacturing method of the present invention, the number of steps in either synthetic route A or B is 8 or 7, and it is not necessary to go through a large number of steps. In addition, the steps (A-1) to (A-8) of synthetic route A and the steps (B-1) to (B-7) of synthetic route B do not require microwave and column purification steps, and can efficiently manufacture a high-yield, high-purity compound, making it suitable for mass production.
[0085] In addition, the compounds represented by the chemical formulas 1 to 11 and the chemical formula Ia, which are prepared and used in the steps (A-1) to (A-8) and the steps (B-1) to (B-7), are all useful intermediates for preparing the triazolopyrimidinone derivative compound represented by the chemical formula I. Effect of the Invention
[0086] The manufacturing method of the present invention has fewer steps than conventional manufacturing methods, and by developing efficient processes, it is possible to produce triazolopyrimidinone derivative compounds with high purity and high yield through crystallization without column purification without using microwave reactions, which significantly reduces the production cost, making it economical and suitable for mass production. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0087] In the following, preferred examples are presented to aid in understanding the present invention. However, the following examples are merely provided to facilitate understanding of the present invention, and are not intended to limit the scope of the present invention. EXAMPLES
[0088] In Example 1 of the present invention, a triazolopyrimidinone derivative compound represented by chemical formula I was prepared according to the following reaction scheme I. [ka]
[0089] Step 1: Preparation of 7-isopropoxy-3-methyl-5-(methylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine
[0090] 3-Methyl-5-(methylthio)-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (15g, 76.1mmol) was diluted in 76mL of dimethylformamide. After adding cesium fluoride (46.2g, 304.2mmol) and isopropyl iodide (38.1g, 228.2mmol), the internal temperature was raised to 75-80°C and stirred for 2 hours. When the reaction was completed, it was cooled to room temperature, 300mL of ethyl acetate was added, and the mixture was stirred for 10 minutes. The formed crystals were filtered through Celite filtration, and 120mL of 5% salt water was added to the filtrate and stirred for 10 minutes. The organic layer was washed twice more with 120mL of 5% salt water. After dehydration with anhydrous sodium sulfate, it was filtered and concentrated under reduced pressure. 50 mL of isopropanol was added to the concentrated residue, and the mixture was heated to 40° C. and stirred for 30 minutes. The precipitated crystals were stirred at 5 to 10° C. for 30 minutes, filtered, and dried under reduced pressure to obtain the title compound (11.3 g, 62%) as a pale yellow solid.
[0091] 1 H-NMR 400 Hz (DMSO-d6): 5.62 (m, 1H), 4.15 (s, 3H), 2.61 (s, 3H), 1.44 (d, J = 8 Hz, 6H). LCMS (ESI, m / z): 240.1 [M+H + ].
[0092] Step 2: Preparation of 7-isopropoxy-3-methyl-5-(methylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine
[0093] 7-Isopropoxy-3-methyl-5-(methylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (10g, 41.8mmol) prepared in step 1 was diluted in 70mL of tetrahydrofuran, cooled to an internal temperature of 5-10°C, and stirred. Oxone (38.5g, 125.3mmol) was dissolved in 200mL of purified water, and then added dropwise to the reaction solution for 30 minutes. After the addition was completed, the internal temperature was raised to 35-40°C and stirred for 2 hours. When the reaction was completed, the reaction solution was concentrated under reduced pressure, 100mL of dichloromethane was added, and the organic layer was extracted. 100mL of dichloromethane was added to the aqueous layer for extraction, and the organic layers were combined, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 50mL of isopropanol was added to the concentrated residue, heated to 75°C, and stirred for 30 minutes. The precipitated crystals were stirred at 5 to 10° C. for 30 minutes, filtered, and dried under reduced pressure to obtain the title compound (9.9 g, 87%) as a pale white solid.
[0094] 1 H-NMR 400 Hz (DMSO-d6): 5.74 (m, 1H), 4.30 (s, 3H), 3.47 (s, 3H), 1.50 (d, J = 6.4 Hz, 6H). LCMS (ESI, m / z): 272.0 [M+H + ].
[0095] Step 3: Preparation of tert-butyl 4-(2,6-difluoro-4-formylphenyl)piperazine-1-carboxylate
[0096] 3,4,5-Trifluorobenzaldehyde (5g, 31.2mmol), Boc-piperazine (5.8g, 31.2mmol), and lithium carbonate (7.3g, 94mmol) were diluted in dimethylsulfoxide (25mL) and stirred at an internal temperature of 115-120°C for 3 hours. When the reaction was completed, the reaction solution was cooled to room temperature, diluted with a mixture of 125mL of cold water and 50mL of ethyl acetate, and stirred for 10 minutes. Insoluble matter was removed through celite filtration. The organic layer of the filtrate was separated, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was used for the next reaction without purification.
[0097] Step 4: Preparation of tert-butyl 4-(2,6-difluoro-4-hydroxyphenyl)piperazine-1-carboxylate
[0098] The tert-butyl 4-(2,6-difluoro-4-formylphenyl)piperazine-1-carboxylate prepared in step 3 was dissolved in 102 mL of dichloromethane, cooled to an internal temperature of -15 to -10°C, and stirred. Metachloroperbenzoic acid (8.08 g, 46.8 mmol) was slowly added dropwise, and the internal temperature was maintained at -10 to 10°C and stirred for 2 hours. 2N aqueous sodium hydroxide solution (78 mL, 156 mmol) was added dropwise to the reaction solution, and the temperature was gradually raised to room temperature and stirred for 2 hours. When the reaction was completed, the aqueous layer was separated and adjusted to pH 6 using 1N aqueous hydrochloric acid solution at 0 to 5°C, and then 90 mL of tert-butyl methyl ether was added and stirred for 10 minutes. The organic layer was extracted and washed with 30 mL of aqueous sodium hydrogen carbonate solution. The solution was dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 35 mL of isopropanol was added to the residue, and the solution was stirred at room temperature for 3 hours. Filtration and drying in vacuo afforded the title compound (3.9 g, 40%) as a pale yellow solid.
[0099] 1 H-NMR 400 Hz (MeOD): 6.33 (d, J = 8.2 Hz, 2H), 4.63 (S, 1H), 3.52 (S, 4H), 3.00 (S, 4H), 1.49 (S, 9H). LCMS (ESI, m / z): 315.1 [M+H + ].
[0100] Step 5: Preparation of tert-butyl 4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazine-1-carboxylate
[0101] Tert-butyl 4-(2,6-difluoro-4-hydroxyphenyl)piperazine-1-carboxylate (20 g, 63.6 mmol) prepared in step 4 was diluted in acetonitrile. Calcium carbonate (26.4 g, 190.9 mmol) and 1-bromo-2-methoxyethane (13.3 g, 95.5 mmol) were added, and the mixture was heated to 75-85° C. and stirred under reflux for 8 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and 140 mL of purified water and 280 mL of ethyl acetate were added to the residue, and the mixture was stirred at room temperature for 15 minutes. The organic layer was separated, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was not purified and the next reaction was carried out.
[0102] Step 6: Preparation of 1-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazine hydrochloride
[0103] 240mL of methanol was added to the reactor, and the internal temperature was cooled to 5°C or less. Then, acetyl chloride (31.3mL, 439mmol) was slowly added and stirred for 15 minutes. The tert-butyl 4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazine-1-carboxylate prepared in step 5 was dissolved in 64mL of dichloromethane and gradually added to the reactor. The internal temperature was raised to 40-45°C and stirred for 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and 60mL of methanol was added to the residue and stirred at room temperature to dissolve. The internal temperature was cooled to 15-20°C, and 180mL of tert-butyl methyl ether was added dropwise and stirred for 30 minutes. The precipitated crystals were filtered and dried under reduced pressure to obtain the title compound (14.2g, 72%) as a pale white solid.
[0104] 1 H-NMR 400 Hz (DMSO-d6): 9.25 (brs, 2H), 6.85-6.64 (m, 2H), 4.12-4.02 (m, 2H), 3.65-3.58 (m, 2H), 3.28 (s, 3H), 3.25-3.18 (m, 4) H), 3.17-3.09(m, 4H). LCMS (ESI, m / z): 273.0 [M+H + ]. (Free form)
[0105] Step 7: Preparation of 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine
[0106] 7-Isopropoxy-3-methyl-5-(methylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (10 g, 36.9 mmol) prepared in step 2 was diluted in 146 mL of ethanol, and diisopropylethylamine (19.3 mL, 110.5 mmol) and 1-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazine hydrochloride (13.1 g, 42.4 mmol) prepared in step 6 were added, and the mixture was heated to 60-80 ° C. and refluxed and stirred for 3 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and 150 mL of dichloromethane and 53 mL of water were added to the residue, and the layers were separated. The aqueous layer was extracted twice with 50 mL of dichloromethane. The organic layers were combined, washed with 50 mL of 1N aqueous hydrochloric acid and 50 mL of 5% salt water, dehydrated with anhydrous sodium sulfate, and then filtered. 2 g of activated carbon was added to the filtrate and stirred for 30 minutes. The filtrate was filtered through Celite and concentrated under reduced pressure. 30 mL of dichloromethane was added to the concentrated residue and dissolved, after which 200 mL of diisopropyl ether was added dropwise and stirred at 5 to 10°C for 1 hour. The precipitated crystals were filtered and dried under reduced pressure to obtain the title compound (15.1 g, 89%) as a pale white solid.
[0107] 1 H-NMR 400 Hz (DMSO-d6): 6.77-6.69(m, 2H), 5.55(m, 1H), 4.09-4.06(m, 2H), 3.99(s, 3H), 3.93(t, J = 4.8 Hz, 4H), 3.64-3.62(m, 2H), 3.28(s, 3H), 3.09(t, J = 4.8 Hz, 4H), 1.42(d, J = 6.4 Hz, 6H). LCMS (ESI, m / z): 464.1 [M+H + ].
[0108] Step 8: Preparation of 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-3-methyl-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
[0109] 92mL of acetic acid and 16.1mL of sulfuric acid were added to 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (15g, 32.4mmol) prepared in step 7, and the internal temperature was raised to 45-50°C and stirred for 3 hours. After the reaction was completed, the reaction solution was cooled to room temperature, and 230mL of purified water was added dropwise for 30 minutes and stirred. After the addition was completed, the internal temperature was cooled to 5-10°C and stirred for 1 hour. The precipitated crystals were filtered and diluted with 150mL of acetone, and the internal temperature was raised to 40-45°C and stirred for 1 hour. The reaction solution was gradually cooled to 5-10°C and 150mL of purified water was added. The precipitated crystals were stirred for 30 minutes, filtered, and dried under reduced pressure to give the title compound (11.5 g, 84%) as a pale white solid.
[0110] 1 H-NMR 400 Hz (DMSO-d6): 11.29(brs, 1H), 6.74(d, J = 11.2 Hz, 2H), 4.08(t, J = 4.4 Hz, 2H), 3.92(s, 3H), 3.82-3.76(m, 4H), 3.62(t, J = 4.4 Hz, 2H), 3.29(s, 3H), 3.12-3.06(m, 4H). LCMS (ESI, m / z): 422.1 [M+H + ]. EXAMPLES
[0111] In Example 2 of the present invention, a triazolopyrimidinone derivative compound represented by Formula I was prepared according to the following Reaction Scheme II. [ka]
[0112] Step 1: Preparation of 3,5-difluoro-4-(piperazin-1-yl)benzaldehyde
[0113] 3,4,5-Trifluorobenzaldehyde (4g, 24.99mmol), piperazine (6.46g, 75mmol), and potassium carbonate (6.91g, 50mmol) were diluted in dimethoxyethane (50mL) and stirred at an internal temperature of 75-80°C for 20 hours. When the reaction was completed, the reaction solution was cooled to 0-5°C and 2N aqueous hydrochloric acid was added to adjust the pH to 2. The aqueous layer was washed twice with 50mL of dichloromethane and then neutralized using 1N aqueous caustic soda solution. After adding 100mL of dichloromethane to the aqueous layer, the organic layer was extracted, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the title compound (4.65g, 82%) as a yellow solid.
[0114] 1 H-NMR 400 Hz (DMSO-d6): 9.80 (s, 1H), 7.56-7.54 (d, J = 8.2 Hz, 2H), 3.19 (s, 4H), 2.79 (s, 4H). LCMS (ESI, m / z): 227.1 [M+H + ].
[0115] Step 2: Preparation of 3,5-difluoro-4-(4-(7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)piperazin-1-yl)benzaldehyde
[0116] 7-Isopropoxy-3-methyl-5-(methylsulfonyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidine (1 g, 3.69 mmol) prepared in step 2 of Example 1 and 3,5-difluoro-4-(piperazin-1-yl)benzaldehyde (0.959 g, 4.24 mmol) prepared in step 1 of Example 2 were diluted in 15 mL of dimethylacetamide, heated to 110-120°C, and stirred for 2 hours. After the reaction was completed, the reaction solution was cooled to room temperature, and 75 mL of ethyl acetate and 30 mL of water were added and diluted, and the organic layer was separated and washed with salt water. The organic layer was dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 5 mL of isopropanol was added to the concentrated residue and stirred at room temperature for 30 minutes. The precipitated crystals were filtered, washed with isopropanol, and then dried under reduced pressure to obtain the title compound (1.25 g, 81%) as a pale yellow solid.
[0117] 1 H-NMR 400 Hz(CDCl3):9.81(s, 1H), 7.44-7.36(m, 2H), 5.65-5.55(m, 1H), 4.07(s, 3H), 4.05-4.03(t, J = 5.0 Hz, 4H), 3.43(s, 4H), 1.50-1.48(d, J = 6.2 Hz, 6H). LCMS (ESI, m / z): 418.0 [M+H + ].
[0118] Step 3: Preparation of 3,5-difluoro-4-(4-(7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)piperazin-1-yl)phenol
[0119] 3,5-difluoro-4-(4-(7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)piperazin-1-yl)benzaldehyde (1g, 2.4mmol) prepared in step 2 was diluted in 8mL of dichloromethane, and then metachloroperbenzoic acid (1076mg, 4.8mmol) was slowly added dropwise at -10 to 0°C, and the internal temperature was maintained at -10 to 10°C and stirred for 2 hours. 2N aqueous sodium hydroxide solution (9.6mL, 19.2mmol) was added dropwise to the reaction solution, and the temperature was gradually raised to room temperature and stirred for 2 hours. When the reaction was completed, the aqueous layer was separated and adjusted to pH 6 using 1N aqueous hydrochloric acid solution at 0 to 5°C, and then 50mL of tert-butyl methyl ether was added and stirred for 10 minutes. The organic layer was extracted and washed with 10mL of aqueous sodium hydrogen carbonate solution. The mixture was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 3 mL of isopropanol was added to the residue, and the mixture was stirred at room temperature for 1 hour. The mixture was filtered and dried under reduced pressure to obtain the title compound (388 mg, 40%) as a pale yellow solid.
[0120] 1 H-NMR 400 Hz (DMSO-d6): 6.44-6.42 (d, J = 11.0 Hz, 2H), 5.57-5.51 (m, 1H), 3.99 (s, 3H), 3.92 (s, 3H), 1.42-1.41 (d, J = 6.2 Hz, 6H). LCMS (ESI, m / z): 406.0 [M+H + ].
[0121] Step 4: Preparation of 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine
[0122] 3,5-Difluoro-4-(4-(7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)piperazin-1-yl)phenol (1g, 2.5mmol) prepared in step 3 was diluted in 10mL of dimethylformamide, and then potassium carbonate (1.02g, 7.4mmol) was added and stirred at 65-70°C for 7 hours. After the reaction was completed, 200mL of purified water and 550mL of ethyl acetate were added and stirred at room temperature for 15 minutes. The organic layer was separated, dehydrated with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. Dichloromethane and diisopropyl ether were added dropwise to the concentrated residue to precipitate crystals. The precipitated crystals were filtered and dried under reduced pressure to obtain the title compound (780mg, 68%) as a pale white solid.
[0123] 1 H-NMR 400 Hz(DMSO-d6):6.77-6.69(m, 2H), 5.55(m, 1H), 4.09-4.06(m, 2H), 3.99(s, 3H), 3.93(t, J = 4.8 Hz, 4H), 3.64-3.62(m, 2H), 3.28(s, 3H), 3.09(t, J = 4.8 Hz, 4H), 1.42(d, J = 6.4 Hz, 6H). LCMS (ESI, m / z): 464.1 [M+H + ].
[0124] Step 5: Preparation of 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-3-methyl-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one
[0125] 4.6mL of acetic acid and 0.81mL of sulfuric acid were added to 5-(4-(2,6-difluoro-4-(2-methoxyethoxy)phenyl)piperazin-1-yl)-7-isopropoxy-3-methyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (750mg, 1.62mmol) prepared in step 4, and the internal temperature was raised to 45-50°C and stirred for 3 hours. After the reaction was completed, the reaction solution was cooled to room temperature, and 11mL of purified water was added dropwise for 30 minutes and stirred. After the addition was completed, the internal temperature was cooled to 5-10°C and stirred for 1 hour. The precipitated crystals were filtered and diluted with 7.5mL of acetone, and the internal temperature was raised to 40-45°C and stirred for 1 hour. The reaction solution was gradually cooled to 5-10°C and 7.5mL of purified water was added. The precipitated crystals were stirred for 30 minutes, filtered, and dried under reduced pressure to give the title compound (575 mg, 84%) as a pale white solid.
[0126] 1 H-NMR 400 Hz (DMSO-d6): 11.29 (brs, 1H), 6.74 (d, J = 11.2 Hz, 2H), 4.08 (t, J = 4.4 Hz, 2H), 3.92 (s, 3H), 3.82-3.76 (m, 4H), 3.62 (t, J = 4.4 Hz, 2H), 3.29(s, 3H), 3.12-3.06(m, 4H). LCMS (ESI, m / z): 422.1 [M+H + ].
[0127] Although certain parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. (A-1) A first step of preparing a compound represented by the following chemical formula 2 by a protection reaction from a compound represented by the following chemical formula 1 or a salt thereof: (A-2) a second step of preparing a compound represented by the following formula 3 from the compound represented by the formula 2 by oxidation reaction; (A-3) A third step of preparing a compound represented by the following formula 5 from a compound represented by the following formula 4 by an amination reaction: (A-4) a fourth step of preparing a compound represented by the following formula 6 from the compound represented by the formula 5 by Dakin reaction; (A-5) a fifth step of preparing a compound represented by the following formula 7 from the compound represented by the formula 6 by alkylation reaction; (A-6) a sixth step of preparing a compound represented by the following formula 8 or a salt thereof from the compound represented by the formula 7 by a deprotection reaction: (A-7) a seventh step of preparing a compound represented by the following formula Ia by an amination reaction of the compound represented by formula 3 and the compound represented by formula 8 or a salt thereof; and (A-8) Step 8 of preparing a compound represented by the following formula I from the compound represented by formula Ia by a deprotection reaction; A method for producing a triazolopyrimidinone derivative, comprising: 【Chemistry 1】 【Chemistry 2】 【Chemistry 3】 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】 【Chemistry 7】 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 In the above chemical formula, R is an O-protecting group; A is an N-protecting group.
2. R is C 1 -C 6 The method according to claim 1, wherein the aryl group is alkyl, acetyl, benzoyl, benzyl, p-methoxybenzyl, MOM (methoxymethyl acetal), THP (tetrahydropyran) or silyl ether.
3. The method according to claim 1, wherein A is -Boc, -Cbz, -Fmoc, -benzyl, p-methoxybenzyl, trityl or DMT (dimethoxytrityl).
4. The method according to claim 3, wherein A is -Boc.
5. The method according to claim 1, wherein the step (A-2) comprises reacting with at least one oxidizing agent selected from the group consisting of hydrogen peroxide, benzoyl peroxide, metachloroperbenzoic acid, and oxone.
6. The method of claim 5 , wherein the oxidizing agent is oxone.
7. The method according to claim 1, wherein the step (A-4) comprises reacting with one or more oxidizing agents selected from the group consisting of hydrogen peroxide, ammonium persulfate, and metachloroperbenzoic acid (mCPBA).
8. The method of claim 7, wherein the oxidizing agent is metachloroperbenzoic acid (mCPBA).
9. (B-1) A first step of preparing a compound represented by the following chemical formula 2 by a protection reaction from a compound represented by the following chemical formula 1 or a salt thereof: (B-2) a second step of preparing a compound represented by the following formula 3 from the compound represented by the formula 2 by oxidation reaction; (B-3) A third step of preparing a compound represented by the following formula 9 from a compound represented by the following formula 4 by an amination reaction: (B-4) A fourth step of preparing a compound represented by the following formula 10 from a compound represented by the following formula 9 by an amination reaction: (B-5) a fifth step of preparing a compound represented by the following formula 11 from a compound represented by the following formula 10 by Dakin reaction; (B-6) a sixth step of preparing the compound represented by the following formula Ia by alkylation reaction of the compound represented by the following formula 11; and (B-7) A sixth step of preparing a compound represented by the following chemical formula I by a deprotection reaction from the compound represented by the chemical formula Ia: A method for producing a triazolopyrimidinone derivative, comprising: 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 In the above chemical formula, R is an O-protecting group.
10. R is C 1 -C 6 The method according to claim 9, wherein the aryl group is alkyl, acetyl, benzoyl, benzyl, p-methoxybenzyl, MOM (methoxymethyl acetal), THP (tetrahydropyran) or silyl ether.
Citation Information
Patent Citations
Pyrrolopyrimidines as inhibitors of cysteine proteases
JP2005502683A
Acylated piperidines as glycine transporter inhibitors
JP2008532969A
Pyrazolopyrimidone and Pyrazolopyrimone inhibitors of Tankirase
JP2015518870A
Tankirase-mediated pyrrolopyrimidone and pyrrolopyrimidone inhibitors
JP2015522557A
Novel triazolopyrimidinone or triazolopyridinone derivative, and uses thereof
JP2017521439A
